https://www.selleckchem.com/pr....oducts/abbv-2222.htm
0 (1.0, 4. days. 6-month mortality was 17.4%. Device migration occurred in one patient (2.4%) during follow-up. Transthoracic echocardiography at 6 months after operation showed TR was significantly reduced (none/trivial in 33, mild in 4 and moderate in 1) and the primary safety end point was achieved in 38 cases (82.6%). Patients suffered from peripheral oedema and ascites decreased from 100.0% and 47.8% at baseline to 2.6% and 0.0% at 6 months. The present study showed TTVR was feasible, safe and with low complication rates in pat
Curtir
Comentario
Compartilhar
